Peptide Library

Human study PLS-00040

Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study.

Cross-sectional study · 180 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study.primary · Journal of clinical medicine · 2026-05-22 · PMID 42278864 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients with Hashimoto's thyroiditis and age- and sex-matched healthy controls
Conditions
Hashimoto's thyroiditis
Planned enrollment (registry)
Not reported
Enrolled
180
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Circulating MOTS-c is markedly lower in Hashimoto's thyroiditis and is independently associated with insulin resistance and autoimmune burden. The authors suggest impaired mitochondrial signaling may contribute to thyroid autoimmunity and that MOTS-c is a promising biomarker.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate endpoint: Endogenous MOTS-c was measured as a biomarker. The compound was never administered, so no effect of giving it can be inferred.
    • confounding: The cross-sectional association design cannot establish causality between MOTS-c levels and disease or metabolic status.
    • abstract only: Only the abstract is available, and its result statistics are truncated ("p p p p"), so values cannot be extracted.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 42278864, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 42278864, title (title) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 42278864, abstract (Results, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 42278864, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 42278864, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).